Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 2NET 1Endocrine 1

Conditions

Somatostatinoma 1Neurologic Manifestations 1Neuroendocrine Tumors 1Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

selpercatinib 3Trastuzumab 2Oxaliplatin 2Melphalan 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1sargramostim 1repotrectinib 1pralsetinib 1mercaptoundecahydrododecaborate 1entinostat 1aldesleukin 1Suramin 1Rose Bengal 1Ritonavir 1Radiotherapy 1Quality of Life 1Patient Reported Outcome Measures 1Patient Navigation 1Paclitaxel 1Molecular Diagnostic Techniques 1Microscopy, Electron 1Leucovorin 1Interleukin-12 Subunit p35 1Interleukin-12 1Indinavir 1Immunotherapy 1Floxuridine 1Fentanyl 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × Cytidine Triphosphate × Endocrine × Clear all
NCT01163526 2017-01-30

Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies

Stanford University

Terminated
13 enrolled
EndocrineGastrointestinalNET

Colonic Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Neurologic Manifestations, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡